Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
“We are excited to have Rick join the Collegium leadership team. He brings with him more than 25 years of experience across all stages of product development, as well as clinical and operational expertise,” said
Most recently, Dr. Malamut served as Chief Medical Officer, Head of Research and Development and Senior Vice President for
Dr. Malamut earned his medical degree from
“My experience in developing medicines for pain management equip me with a unique perspective to apply to the advancement and expansion of Collegium’s pain portfolio,” said Dr. Malamut. “I am thrilled to be joining a company with a deep commitment to offering differentiated and innovative treatment options for people suffering from pain and look forward to contributing to the success of Collegium.”
Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts,“ “forecasts,” "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including our ability to obtain and maintain regulatory approval of our products and product candidates; our ability to effectively commercialize in-licensed products and manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the outcome of any patent infringement or other litigation that may be brought by or against us, including litigation with
Source: Collegium Pharmaceutical, Inc.